IP Library Granted Patent US 10,894,779
Granted Patent B2
US 10,894,779 · App. 16/489,260 · Granted Jan 19, 2021

Process for producing flutametamol

Inventors: Yuki Okumura (Tokyo, JP); Gota Tonoya (Tokyo, JP); Tomoyuki Matsunami (Tokyo, JP); Kei Akama (Tokyo, JP)
Assignee: GE HEALTHCARE LIMITED
C07D277/66C07B59/002C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,894,779
App. No.
16/489,260
Granted
Jan 19, 2021
Kind
B2
Abstract

The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol. Provided is a process for producing a radioactive fluorine labeled flutemetamol, which comprises: (a) a step of allowing a labeling precursor represented by the predetermined general formula to react with a radioactive fluoride ion in a presence of a solvent to obtain a radioactive fluorine labeled intermediate represented by the predetermined general formula, and (b) a step of removing the protecting groups from the radioactive fluorine labeled intermediate to obtain a radioactive fluorine labeled flutemetamol, in which the above step (a) is carried out at an internal temperature of reaction solution of 140° C. or higher.

Claims (23)

1. A process for producing a radioactive fluorine labeled flutemetamol, which comprises:

(a) reacting a labeling precursor of formula (1)

with a radioactive fluoride ion in a presence of a solvent to obtain a radioactive fluorine labeled intermediate of formula (2)

wherein R 1 is a hydroxy protecting group, and C(O)R 2 is an amino protecting group and X is a radioactive fluorine, and the solvent temperature is greater than 140° C. during the reaction; and

(b) removing the protecting groups from the radioactive fluorine labeled intermediate to obtain a radioactive fluorine labeled flutemetamol.

2. The process according to claim 1 , in which the above step (a) is carried out for a reaction time of 3-10 minutes.

3. The process according to claim 1 , in which the solvent in the above step (a) comprises an organic solvent and water, and includes water in a concentration of 2000 ppm or lower.

4. The process according to claim 3 , in which the solvent is dimethylsulfoxide.

5. The process according to claim 1 , in which the temperature of the solvent is 145-170° C. during the reaction.

6. The process according to claim 1 , wherein the process is conducted in an automated radiopharmaceutical synthesis platform configured for flutemetamol synthesis.

7. The process according to claim 3 , in which the solvent is selected from acetonitrile, dimethylformamide, dimethylsulfoxide, dimethylacetamide, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, sulfolane, N-methylpyrrolidone, 1-ethyl-3-methylimidazolium hexafluorophosphate, or 1-butyl-4-methylpyridinium tetrafluoroborate.

8. The process according to claim 3 , in which the solvent is an imidazolium derivative, pyridinium derivative, or a tetraalkylammonium compound.

9. A process for producing a radioactive fluorine labeled flutemetamol, which comprises:

(a) reacting a labeling precursor of formula (1)

with a radioactive fluoride ion in a presence of a solvent and water to obtain a radioactive fluorine labeled intermediate of formula (2)

wherein R 1 is a hydroxy protecting group, and C(O)R 2 is an amino protecting group and X is a radioactive fluorine, the temperature of the solvent is 145-170° C. during the reaction; and

(b) removing the protecting groups from the radioactive fluorine labeled intermediate to obtain a radioactive fluorine labeled flutemetamol.

10. The process according to claim 9 , in which the above step (a) is carried out for a reaction time of 3-10 minutes.

11. The process according to claim 9 , in which the solvent in the above step (a) includes water in a concentration of 2000 ppm or lower.

12. The process according to claim 9 , in which the solvent is dimethylsulfoxide.

13. The process according to claim 9 , wherein the process is conducted in an automated radiopharmaceutical synthesis platform configured for flutemetamol synthesis.

14. The process according to claim 9 , in which the solvent is selected from acetonitrile, dimethylformamide, dimethylsulfoxide, dimethylacetamide, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, sulfolane, N-methylpyrrolidone, 1-ethyl-3-methylimidazolium hexafluorophosphate, or 1-butyl-4-methylpyridinium tetrafluoroborate.

15. The process according to claim 9 , in which the solvent is an imidazolium derivative, pyridinium derivative, or a tetraalkylammonium compound.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2023
From: EASTWARD FUND MANAGEMENT, LLC
To: INTEGRITY IMPLANTS INC.
Reel/Frame 065536/0632 →
SECURITY INTEREST Recorded Jun 18, 2021
From: INTEGRITY IMPLANTS INC.
To: EASTWARD FUND MANAGEMENT, LLC
Reel/Frame 057079/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2020
From: OKUMURA, YUKI; TONOYA, GOTA; MATSUNAMI, TOMOYUKI; AKAMA, KEI
To: GE HEALTHCARE LIMITED
Reel/Frame 051769/0597 →